SIX Swiss Exchange · Healthcare
Invest in Novartis stock from India
Indian and foreign residents can buy Novartis (NOVN) shares directly through Paasa.
By Paasa · Updated
Novartis at a glance
- Price
- CHF 134.06-CHF 0.16 (0.12%)
- Market cap
- CHF 253.19B
- Day range
- CHF 133.48 – CHF 134.76
- P/E
- 30.76
- Dividend yield
- 2.76%
- Volume
- 3.38M
- 1 month
- +12.37%
- 6 months
- +14.78%
- YTD
- +22.32%
- 1 year
- +26.78%
- 5 years
- +75.89%
Novartis statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $57.1B | $51.7B | $46.7B | $43.5B | $44.0B |
| Gross profit | $42.9B | $38.9B | $34.2B | $31.9B | $32.2B |
| Operating income | $17.8B | $14.5B | $9.8B | $7.9B | $10.1B |
| Net income | $14.6B | $11.9B | $14.8B | $7.0B | $24.0B |
| Earnings per share | $7.56 | $5.92 | $7.11 | $3.19 | $10.71 |
| EBITDA | $24.0B | $20.7B | $18.3B | $14.7B | $30.9B |
| Total assets | $115.5B | $102.2B | $99.9B | $117.5B | $131.8B |
| Total debt | $37.0B | $31.3B | $26.3B | $27.9B | $31.0B |
| Cash and short-term investments | $11.6B | $13.4B | $14.0B | $18.6B | $28.1B |
| Shareholders' equity | $46.1B | $44.0B | $46.7B | $59.3B | $67.7B |
| Operating cash flow | $20.1B | $17.6B | $14.5B | $14.2B | $15.1B |
| Free cash flow | $18.4B | $13.8B | $11.7B | $11.6B | $12.1B |
| Capital expenditure | −$1.6B | −$3.8B | −$2.8B | −$2.7B | −$3.0B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in USD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Eli Lilly | LLY.SW | CHF 1,170.00 | CHF 1.04T |
| Johnson & Johnson | JNJ.SW | CHF 222.05 | CHF 535.12B |
| AbbVie | ABBV | $295.03 | $521.50B |
| Merck | MRK | $147.76 | $364.27B |
| Roche | ROP.SW | CHF 404.70 | CHF 279.27B |
| Amgen | AMGN | $465.67 | $251.89B |
| AstraZeneca | AZN.L | £139.82 | £216.85B |
| Gilead Sciences | GILD | $168.08 | $208.48B |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 5 buy · 14 hold · 1 sell. Consensus: Hold.
Published sell-side 12-month targets in CHF, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Novartis from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to CHF when you buy.
Step 3
Search NOVN and buy
Find Novartis by name or by its ticker, NOVN, and place your order.
Why invest in Novartis from India
What Novartis does
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients w… Novartis operates in the Drug Manufacturers - General industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Novartis stock from India?
Yes. Indian residents and NRIs can buy Novartis (NOVN) shares directly through Paasa. Novartis is listed on the SIX Swiss Exchange, in the Drug Manufacturers - General industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Novartis shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the CHF/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.